Latest news with #EuropeanUrologyOncology
Daily Record
19-05-2025
- Health
- Daily Record
What is the survival rate of Joe Biden's ‘aggressive' prostate cancer after high Gleason score
The former US president has been diagnosed with the disease that has spread to his bones. Former US President Joe Biden has been diagnosed with a serious type of prostate cancer, his office announced on the evening of Sunday (May 18). The 82-year-old was seen last week by doctors after experiencing urinary symptoms, and a prostate nodule was found. Biden was diagnosed with prostate cancer on Friday (May 16) with the cancer cells having spread to the bone, and he is currently considering his treatment options. His office described Biden's form of cancer as 'aggressive'. "While this represents a more aggressive form of the disease, the cancer appears to be hormone-sensitive which allows for effective management," his office said. "The President and his family are reviewing treatment options with his physicians." The former President was given a Gleason score of nine, which suggests his cancer is among the most severe. But as Biden's health makes headlines, along with his dangerously high Gleason score, questions are rising on what exactly a Gleason score is, and what it measures. Here's everything you need to know about the Gleason scoring system. What is the Gleason score? Gleason scores are a system of grading the severity of prostate cancers, explains Cleveland Clinic. When a patient has prostate cancer, medical pathologists study their tissue samples under a microscope, and determine how abnormal the cells are, and how fast they're likely to grow. Gleason scores range from six, which is a low-grade cancer, to 10, a high-grade and more aggressive prostate cancer. Low grade prostate cancer grows more slowly than high-grade cancer, which is more likely to spread to other parts of the body, such as Biden's, which has spread to his bones. Joe Biden's Gleason score of nine indicates that he has a severe and spreading form of prostate cancer. What is the survival rate of a high Gleason score? Higher Gleason scores of nine or 10 generally have a lower survival rate than scores of six or seven. A study published in European Urology Oncology analysed the survival rates of men diagnosed with prostate cancer. Researchers analysed data from 620 patients with various Gleason scores, and it was found that 43 per cent of men with a Gleason score of nine or 10 died of prostate cancer. Of all men with a Gleason score of nine or 10, 34 per cent were alive at the end of the study, which followed up on patients five and 10 years after their diagnoses. While 43 per cent died of prostate cancer, 23 per cent died of other causes. According to AJMC, Biden's Gleason nine cancer which has already spread has a five-year survival rate of 37 per cent, which is significantly lower than early-stage detection. The former US President's health has been widely discussed and speculated since he was elected in 2020. And he faced several health problems during his time in office. In February 2023, Biden had a skin lesion removed from his chest that was a basal cell carcinoma, a common form of skin cancer. And in November 2021, he had a polyp removed from his colon that was a benign, but potentially pre-cancerous lesion. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'.
Yahoo
25-03-2025
- Health
- Yahoo
Urine test could help spot recurring kidney cancer, researchers say
A simple urine test could accurately detect recurring kidney cancer in patients recovering from surgery for the disease, potentially sparing them from frequent follow-up scans, researchers suggest. The AUR87A study, led by Swedish researchers, included 134 patients who were treated at 23 hospitals in the UK, Europe, US and Canada. All had been diagnosed with clear cell renal cell carcinoma (ccRCC) – the most common type of kidney cancer – which had not spread beyond the kidney and was treated with surgery. Most patients had their kidney completely removed. This type of cancer returns in about a fifth of people, usually within one to two years. Patients are monitored with CT scans, with their frequency based on the level of individual risk. For the study, the group continued to have CT scans as part of their standard monitoring after the operation, alongside a urine test every three months. These tests analysed the profiles of certain sugar molecules in the urine, known as glycosaminoglycans, and gave patients a score out of 100, known as the GAGome score. After 18 months, cancer had returned in 15% of the group. The study found the urine test correctly detected recurrence in 90% of these patients. It also correctly ruled out recurring cancer in a little over half the patients who remained cancer-free. Saeed Dabestani, associate professor at Lund University and consultant urologist at Kristianstad Central Hospital in Sweden, said: 'CT scans often pick up small lesions that aren't large enough to biopsy, and we currently don't know whether they are a sign of the cancer returning or not. 'Our only option is to do more frequent scans to monitor more closely, which is unpleasant for patients and often brings little benefit. 'If you have a urine test that can accurately show whether the cancer has actually returned then you can better assess risk levels and reduce the frequency of the scans required. 'Based on the results we have so far, it's likely that we could safely halve the number of scans that patients have to undergo.' The findings are being presented at the at the European Association of Urology (EAU) Congress in Madrid and have been accepted for publication in the journal European Urology Oncology. Researchers are currently recruiting a second group of patients for the AUR87A study, which results expected towards the end of the year.
The Independent
24-03-2025
- Health
- The Independent
Urine test ‘could help spot recurring kidney cancer', researchers suggest
A simple urine test could accurately detect recurring kidney cancer in patients recovering from surgery for the disease, potentially sparing them from frequent follow-up scans, researchers suggest. The AUR87A study, led by Swedish researchers, included 134 patients who were treated at 23 hospitals in the UK, Europe, US and Canada. All had been diagnosed with clear cell renal cell carcinoma (ccRCC) – the most common type of kidney cancer – which had not spread beyond the kidney and was treated with surgery. Most patients had their kidney completely removed. This type of cancer returns in about a fifth of people, usually within one to two years. Patients are monitored with CT scans, with their frequency based on the level of individual risk. For the study, the group continued to have CT scans as part of their standard monitoring after the operation, alongside a urine test every three months. These tests analysed the profiles of certain sugar molecules in the urine, known as glycosaminoglycans, and gave patients a score out of 100, known as the GAGome score. After 18 months, cancer had returned in 15% of the group. The study found the urine test correctly detected recurrence in 90% of these patients. It also correctly ruled out recurring cancer in a little over half the patients who remained cancer-free. Saeed Dabestani, associate professor at Lund University and consultant urologist at Kristianstad Central Hospital in Sweden, said: 'CT scans often pick up small lesions that aren't large enough to biopsy, and we currently don't know whether they are a sign of the cancer returning or not. 'Our only option is to do more frequent scans to monitor more closely, which is unpleasant for patients and often brings little benefit. 'If you have a urine test that can accurately show whether the cancer has actually returned then you can better assess risk levels and reduce the frequency of the scans required. 'Based on the results we have so far, it's likely that we could safely halve the number of scans that patients have to undergo.' The findings are being presented at the at the European Association of Urology (EAU) Congress in Madrid and have been accepted for publication in the journal European Urology Oncology. Researchers are currently recruiting a second group of patients for the AUR87A study, which results expected towards the end of the year.
Yahoo
24-03-2025
- Health
- Yahoo
Urine test ‘could help spot recurring kidney cancer', researchers suggest
A simple urine test could accurately detect recurring kidney cancer in patients recovering from surgery for the disease, potentially sparing them from frequent follow-up scans, researchers suggest. The AUR87A study, led by Swedish researchers, included 134 patients who were treated at 23 hospitals in the UK, Europe, US and Canada. All had been diagnosed with clear cell renal cell carcinoma (ccRCC) – the most common type of kidney cancer – which had not spread beyond the kidney and was treated with surgery. Most patients had their kidney completely removed. This type of cancer returns in about a fifth of people, usually within one to two years. Patients are monitored with CT scans, with their frequency based on the level of individual risk. For the study, the group continued to have CT scans as part of their standard monitoring after the operation, alongside a urine test every three months. These tests analysed the profiles of certain sugar molecules in the urine, known as glycosaminoglycans, and gave patients a score out of 100, known as the GAGome score. After 18 months, cancer had returned in 15% of the group. The study found the urine test correctly detected recurrence in 90% of these patients. It also correctly ruled out recurring cancer in a little over half the patients who remained cancer-free. Saeed Dabestani, associate professor at Lund University and consultant urologist at Kristianstad Central Hospital in Sweden, said: 'CT scans often pick up small lesions that aren't large enough to biopsy, and we currently don't know whether they are a sign of the cancer returning or not. 'Our only option is to do more frequent scans to monitor more closely, which is unpleasant for patients and often brings little benefit. 'If you have a urine test that can accurately show whether the cancer has actually returned then you can better assess risk levels and reduce the frequency of the scans required. 'Based on the results we have so far, it's likely that we could safely halve the number of scans that patients have to undergo.' The findings are being presented at the at the European Association of Urology (EAU) Congress in Madrid and have been accepted for publication in the journal European Urology Oncology. Researchers are currently recruiting a second group of patients for the AUR87A study, which results expected towards the end of the year.
